# VX-950 and Peginterferon for Hepatitis C

> **NCT00251199** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 20 (—)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** VX-950
- **DRUG:** peginterferon

## Key facts

- **NCT ID:** NCT00251199
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 20 (—)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251199, "VX-950 and Peginterferon for Hepatitis C". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00251199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*